Kyoto University Innovation Capital has taken part in a $19.3m round for the cell-derived heart therapy spinout of Osaka University.

Cuorips, a Japan-based cell therapy spinout of Osaka University, has raised ¥2bn ($19.3m) from investors including Kyoto University Innovation Capital (KU-iCap), an investment vehicle for Kyoto University.
Medical equipment producer Asahi Intecc, construction firm Dai-Dan, cord blood bank StemCell Institute and pharmaceutical firm Taiko Pharmaceutical filled out the round.
Founded in early 2017 as Cuore, the spinout renamed Cuorips later in the year. It is working on a cell-derived therapy mainly composed of cardiomyocytes, the cells that make…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.



Not sure if you have a subscription?
Edison Fu

Edison Fu is a reporter and Asia liaison at Global Corporate Venturing.
email
Linked in